Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Metitepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A known ✓ | Q03164 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.82 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.82 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.82 |
| ▸ | MTOR known ✓ | P42345 | 2/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.61 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metitepine SCHEMBL2048660 | 1.00 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL113526 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL14359602 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL7517783 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL29496251 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Maleic Acid SCHEMBL11878955 | 0.89 | MAPT (0.80) | MAPTTP53CYP3A4MEN1LMNA | |
| Fumaric Acid SCHEMBL11878965 | 0.89 | MAPT (0.80) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL31360614 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL466985 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Fumaric Acid SCHEMBL11876998 | 0.87 | MAPT (0.76) | MAPTTP53CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161375-A1 | METHODS OF DECREASING DYSBIOSIS AND RESTORING A MICROBIOME | VEDANTA BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12161680-B2 | Methods of decreasing dysbiosis and restoring a microbiome | VEDANTA BIOSCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230330157-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2023-10-19 | — | — | US | disclosed |
| US-11690880-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2023-07-04 | — | — | US | disclosed |
| US-20230126159-A1 | ENGINEERED BACTERIAL STRAINS COMPRISING A TRANSGENE | ELIGO BIOSCIENCE (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230114520-A1 | ENGINEERED BIFIDOBACTERIUM STRAINS COMPRISING A TRANSGENE | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20230113800-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | US | disclosed |
| WO-2023057598-A1 | METHODS INVOLVING BACTERIAL STRAIN REPLACEMENT | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | WO | disclosed |
| US-11534467-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2022-12-27 | — | — | US | disclosed |
| WO-2021204967-A9 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2022-11-10 | — | — | WO | disclosed |
| US-20220233610-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2022-07-28 | — | — | US | disclosed |
| US-11376286-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2022-07-05 | — | — | US | disclosed |
| US-20220143108-A1 | METHODS OF DECREASING DYSBIOSIS AND RESTORING A MICROBIOME | VEDANTA BIOSCIENCES, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220031767-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2022-02-03 | — | — | US | disclosed |
| US-11224621-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20210315944-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2021-10-14 | — | — | US | disclosed |
| EP-3836946-A1 | METHODS OF DECREASING DYSBIOSIS AND RESTORING A MICROBIOME | Vedanta Biosciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020037271-A1 | METHODS OF DECREASING DYSBIOSIS AND RESTORING A MICROBIOME | VEDANTA BIOSCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |